Skip to the content

Illuminating Precision Oncology - From First Signal to Broad Impact, with Speed and Efficiency

logo mainlogo darklogo light
  • About
    • Leadership Team
    • Scientific & Clinical Advisors
    • Board of Directors
    • Collaborations & Partnerships
  • Technology
  • Product Pipeline
    • EO-1001 Program
    • EO-3001 Program
    • EO-4426 Program
    • OROTECAN® Program
  • News & Media
    • Press Releases
    • Presentations & Publications
  • Contact
  • Careers
logo mainlogo darklogo light
HomePress Release(Page 2)
Press Release

Edison Oncology to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Edison Oncology
February 16, 2021
Press Release

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Edison Oncology
February 9, 2021

Posts pagination

1 2
Recent Updates

Edison Oncology Presents New Preclinical Data onEO1001 and EO4426 Highlighting Differentiated Targetingof Cancer Resistance Pathways at AACR 2026

Edison Oncology
April 23, 2026

Edison Oncology Completes Target Enrollment in Phase 1/2a Orotecan™ Clinical Trial 

Edison Oncology
March 20, 2026
Categories
News Presentations and Publications Press Release
w
Contact us today
View more

Company

  • Leadership Team
  • About
  • Careers

Information

  • Technology
  • Product Pipeline
  • Press Releases

Menlo Park, CA

  • 3475 Edison Way,
    Suite R
    Menlo Park, CA 94025

© 2025 Edison Oncology, All Rights Reserved

Back to top Drag
  • About
    • Leadership Team
    • Scientific & Clinical Advisors
    • Board of Directors
    • Collaborations & Partnerships
  • Technology
  • Product Pipeline
    • EO-1001 Program
    • EO-3001 Program
    • EO-4426 Program
    • OROTECAN® Program
  • News & Media
    • Press Releases
    • Presentations & Publications
  • Contact
  • Careers

John K. Bell

Independent Board Member

John K. Bell serves as lead independent director and chair of the audit committee.

Mr. Bell is the founder of Shred-Tech Ltd. and Polymer Technologies, Inc., John K. Bell is a businessperson who has been the head of 15 different companies and presently is Chairman at CrossChasm Technologies, Inc., Chairman & Chief Executive Officer at Onbelay Investment Corp., Chairman for Stack Capital Group, Inc., lead independent director of Edison Oncology Holding Corp., and Director & Governor at Stratford Festival. He is also on the board of Stratford Shakespearean Festival of America.

Mr. Bell was a founding investor of Research in Motion (Blackberry) and previously held the position of Director at Canopy Growth Corp. and Chairman of Canopy Rivers Corp. (a subsidiary of Canopy Growth Corp.), Chairman of Waterloo Regional Police Service, Chairman of Prosperity Council of Waterloo Region, Director at RIV Capital, Inc., Chief Executive Officer & Director at ATS Corp., Chief Executive Officer & Owner at Shred-Tech Ltd., Director at BSM Technologies, Inc., Director at BSM Technologies Ltd., Chairman of HEXO Corp., President & Chief Executive Officer of Polymer Technologies, Inc., Chairman of Cambridge Memorial Hospital, Member of Institute of Corporate Directors and Secretary & Director at Crohn’s & Colitis Foundation of Canada.

John K. Bell received an undergraduate degree from Richard Ivey School of Business.